Enabling A Four-Fold Increase In Titer For mAb Manufacturing Using Syngene's Platform Process

Efficient monoclonal antibody (mAb) production is essential to meet the growing demand for advanced biologic therapies, particularly in oncology. Yet achieving high titers while maintaining product quality and meeting aggressive timelines remains a persistent challenge for manufacturers.

This case explores how a structured, platform-driven upstream development strategy helped address these challenges by integrating clone selection, process optimization, and scalable production approaches. High-performing clones were identified through systematic screening, while design of experiments (DoE) and bioreactor-based optimization were used to refine key process parameters under controlled conditions.

This data-driven approach enabled faster, more focused development with reduced experimental redundancy, accelerating progress without compromising quality. During scale-up, the process demonstrated strong robustness, delivering significant titer improvements alongside consistent product attributes.

Overall, the methodology highlights how platform expertise and structured decision-making can improve manufacturing efficiency, reduce development costs, and support faster advancement toward clinical and commercial production.